Hounaida Mahfoud on Hemoperitoneum in Case of Type 3 VWD
Hounaida Mahfoud, Assistant Professor at Faculty of Medicine and Pharmacy of Rabat, shared on LinkedIn:
”Delighted to share the publication of our article on a difficult case managed successfully, thanks to my mentor Pr Mohamed El Khorassani and the dedicated ICU team at Hôpital de Maternité Souissi.
Honoured to be part of this work.
Hemoperitoneum secondary to a ruptured hemorrhagic C is usually a benign and self-limiting condition, but in women with type 3 von Willebrand disease (VWD), it may evolve into a severe and potentially life-threatening event due to the inability to achieve spontaneous hemostasis.
We report a case of a 30-year-old woman with type 3 VWD who presented with acute pelvic pain and profound anemia.
Transvaginal ultrasonography and MRI demonstrated a ruptured hemorrhagic ovarian cyst associated with a large hemoperitoneum.
Despite the extent of bleeding, the patient remained hemodynamically stable and was managed conservatively.
Treatment consisted of von Willebrand factor replacement, blood transfusion, analgesia, and close clinical and radiological monitoring.
Her condition improved progressively, with normalization of hemoglobin levels, resolution of symptoms, and significant regression of the hemoperitoneum on follow-up imaging.
No surgical intervention was required. Managing ovarian cyst rupture in severe VMD is particularly challenging, as surgical intervention carries substantial hemorrhagic risk.
Conservative management, when supported by adequate hemostatic therapy, can be both safe and effective, preserving ovarian function and reducing perioperative morbidity.
This case underscores the importance of individualized, multidisciplinary care to optimize management strategies in women with severe bleeding disorders.”
Read the full article here.
Article: Conservative Management of Hemoperitoneum Due to a Ruptured Hemorrhagic Ovarian Cyst in Type 3 von Willebrand Disease
Authors: Hounaida Mahfoud, Rim Laaboudi, Mohamed Elkhorassani, Nabil Elachhab, Samir Bargach
Stay updated on all scientific advances with Hemostasis Today.
-
May 31, 2026, 16:29José Antonio García Erce: Collaborative PBM Implementation in Transfusion Centers and Services
-
May 31, 2026, 16:22Vera Ignjatović: How Do We Rigorously Study These Drugs in Children to Understand Their True Benefits and Risks?
-
May 31, 2026, 16:21Ksenija Stach: Is This The Future of Lipid-Lowering Lherapy?
-
May 31, 2026, 15:42Antonio Greco: Balancing Bleeding and Thrombotic Risk After PCI
-
May 31, 2026, 15:41Eric Topol: Replication of Plasma p-tau217 Blood Test for Predicting Alzheimer’s Disease
-
May 31, 2026, 15:32ASH Invites Dynamic Members to Apply for 2027 Leadership and Committee Roles
-
May 31, 2026, 14:39Monique Gore-Massy: Redefining Lupus Innovation Through Patient Partnership
-
May 31, 2026, 14:31Mirjam Teboe: The Golden Rule Behind Reliable Lupus Anticoagulant Testing
-
May 31, 2026, 14:20Improving Access to Care for People Living with Haemophilia and Haemoglobinopathies – NNHF